Vascular Biology Center, Georgia Health Sciences University, Augusta, GA 30912-2500, USA.
Immunotherapy. 2011 May;3(5):609-28. doi: 10.2217/imt.11.24.
Diabetic retinopathy (DR) is one of the most common complications of diabetes. This devastating disease is a leading cause of blindness in people of working age in industrialized countries and affects the daily lives of millions of people. Despite tight glycemic control, blood pressure control and lipid-lowering therapy, the number of DR patients keeps growing and therapeutic approaches are limited. Moreover, there are significant limitations and side effects associated with the current therapies. Thus, there is a great need for development of new strategies for prevention and treatment of DR. Studies have shown that DR has prominent features of chronic, subclinical inflammation. This article focuses on the role of inflammation in DR and summarizes the progress of studies of anti-inflammatory strategies for DR.
糖尿病性视网膜病变（DR）是糖尿病最常见的并发症之一。这种破坏性疾病是工业化国家劳动年龄段人群失明的主要原因，影响着数以百万计的人的日常生活。尽管进行了严格的血糖控制、血压控制和降脂治疗，DR 患者的数量仍在不断增加，治疗方法也有限。此外，目前的治疗方法还存在显著的局限性和副作用。因此，迫切需要开发新的策略来预防和治疗 DR。研究表明，DR 具有明显的慢性、亚临床炎症特征。本文重点介绍了炎症在 DR 中的作用，并总结了 DR 抗炎策略研究的进展。
